Clinical Trial Finder
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Study Purpose
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Inclusion Criteria:
Exclusion Criteria:
- - history of previous head-and-neck cancers or radiotherapy in the head-and-neck region.
- distant metastases at (chemo-)radiotherapy initiation (cM1) - HNSCCs of the nasopharynx, salivary glands, skin or with unknown primaryTrial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Recruiting
Address
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287
Site Contact
Harry Quon, MD, MS
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai
New York, New York, 10017
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, Case Western Reserve University
Cleveland, Ohio, 10900
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Division of Radiation Oncology, The Ohio State University Wexner
Columbus, Ohio, 43201
Site Contact
[email protected]
004976127095200
International Sites
Status
Completed
Address
Radiation Oncology Department, German Oncology Center
Limassol, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin
Berlin, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main
Frankfurt, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Hospital Schleswig-Holstein
Kiel, ,
Site Contact
[email protected]
004976127095200
Status
Recruiting
Address
Department of Radiation Oncology, University Medical Center Leipzig
Leipzig, ,
Site Contact
Nils H Nicolay, MD, PhD
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Medical Center Mainz
Mainz, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Hospital, LMU Munich
Munich, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Hospital Würzburg
Würzburg, ,
Site Contact
[email protected]
004976127095200
Status
Completed
Address
Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH)
Zürich, ,
Site Contact
[email protected]
004976127095200
Privacy Overview